Halozyme Therapeutics Investor Presentation — June 2020

Document content

Corporate Presentation

Halozyme Therapeutics, Inc.

June 5, 2020 Forward -Looking Statements

Inaddition tohistorical information, the statements setforth inthis presentation include forward -looking

statements including, without limitation, statements concerning the Company’s expected future financial

performance (including theCompany's financial outlook for2020 )and expectations forprofitability, revenue,

free cash flow, expenses and earnings -per-share and theCompany’s plans tocontinue itsshare repurchase

program and topotentially expand itsplatform through acquisitions .Forward -looking statements regarding the

Company’s ENHANZE®drug delivery technology may include thepossible activity, benefits and attributes of

ENHANZE®,thepossible method ofaction ofENHANZE®,itspotential application toaidinthedispersion and

absorption ofother injected therapeutic drugs and facilitating more rapid delivery ofinjectable medications

through subcutaneous delivery .Forward -looking statements regarding theCompany's ENHANZE®business may

include potential growth driven byourpartners' development and commercialization efforts (including expected

approval and product launch ofENHANZE®products), projections forfuture sales revenue ofourcollaborators’

products, potential new ENHANZE®collaborations, collaborative targets and co-formulation intellectual property,

and regulatory review and potential approvals ofnew ENHANZE®products .These forward -looking statements are

typically, butnotalways, identified through useofthewords "believe," "enable," "may," "will," "could," "intends,"

"estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of

similar meaning and involve riskand uncertainties that could cause actual results todiffer materially from those in

theforward -looking statements .Actual results could differ materially from theexpectations contained inthese

forward -looking statements asaresult ofseveral factors, including unexpected levels ofrevenues (including

royalty and milestone revenue received from ourcollaboration partners), expenditures and costs, unexpected

delays intheexecution oftheCompany's share repurchase program orplatform expansion, unexpected results

ordelays inthegrowth oftheCompany’s ENHANZE®business, obtaining new co-formulation intellectual property,

orinthedevelopment, regulatory review orcommercialization ofENHANZE®products, including any potential

delays caused bythe current COVID -19global pandemic, regulatory approval requirements, unexpected